Functional imaging with 18F-FDG PET/CT and diffusion weighted imaging (DWI) in early response evaluation of combination therapy of elotuzumab, lenalidomide, and dexamethasone in a relapsed multiple myeloma patient
Elotuzumab is the first monoclonal antibody approved for the treatment of relapsed-refractory multiple myeloma (MM) in combination with lenalidomide, an immunodulatory drug, and dexamethasone. We report on a multiply pre-treated MM patient with disease progression due to appearance of new focal lesi...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
15 December 2017
|
| In: |
Diagnostics
Year: 2017, Jahrgang: 7, Heft: 4 |
| ISSN: | 2075-4418 |
| DOI: | 10.3390/diagnostics7040061 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.3390/diagnostics7040061 Verlag, kostenfrei, Volltext: http://www.mdpi.com/2075-4418/7/4/61 
|
| Verfasserangaben: | Christos Sachpekidis, Antonia Dimitrakopoulou-Strauss, Stefan Delorme and Hartmut Goldschmidt |
| Zusammenfassung: | Elotuzumab is the first monoclonal antibody approved for the treatment of relapsed-refractory multiple myeloma (MM) in combination with lenalidomide, an immunodulatory drug, and dexamethasone. We report on a multiply pre-treated MM patient with disease progression due to appearance of new focal lesions on imaging modalities, who was started on a combination treatment of elotuzumab, lenalidomide, and dexamethasone. After completion of three cycles of the new therapy the patient responded very well with a major decline of serological myeloma activity parameters serum monoclonal protein, kappa light chains, free light chains (FLC) ratio. The patient was also monitored with the functional imaging modalities 18F-FDG PET/CT and diffusion weighted imaging (DWI), which exhibited a mismatch of almost complete metabolic remission on positron emission tomography/computed tomography (PET/CT) with 18F-fluoro-2-deoxy-d-glucose (18F-FDG) (consistent with the serological response), and signal elevation persistence on DWI. This case demonstrates the potentially superior performance of 18F-FDG PET/CT over DWI in early response evaluation of combined treatment with a monoclonal antibody, an immunomodulatory drug, and dexamethasone in MM. |
|---|---|
| Beschreibung: | Die Zahl 18 ist in der Vorlage hochgestellt Gesehen am 05.06.2018 |
| Beschreibung: | Online Resource |
| ISSN: | 2075-4418 |
| DOI: | 10.3390/diagnostics7040061 |